Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picoplatin and Docetaxel in Metastatic Hormone-Refractory Prostate Cancer
NCT00448734Phase 2Unknown
- Sponsor
- Poniard Pharmaceuticals, Inc.
- Start
- Jun 2006
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of picoplatin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Poniard Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose and Prostate Specific Antigen Response. Status: unknown.
02
Drugs
picoplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00448734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448734.